Abstract 521P
Background
Extensive-stage small-cell lung cancer (ES-SCLC) is an aggressive tumor type with limited therapeutic options and poor prognosis. It is worthy to explore the new treatment pattern in consideration of the rapid disease progression. Therefore, this study aims to explore the effectiveness and safety of camrelizumab combined with chemotherapy and apatinib in the first-line treatment of ES-SCLC.
Methods
In this phase II study, 40 patients with pathological diagnosis of ES-SCLC and without receiving prior systemetic therapy are anticipated to be enrolled, and will be dosed camrelizumab (200 mg, q3w) combined with etoposide (80-100 mg/m2, q3w, 4-6 cycles) and platinum drugs (selected by the researcher according to the patients, q3w, 4-6 cycles), followed by maintenance with camrelizumab and apatinib (250 mg, qd). The primary endpoint is 6-month progress-free survival (6-month PFS) rate while the secondary endpoints are objective response rate (ORR), disease control rate (DCR), progression-free survival, overall survival and safety.
Results
Up to August 20, 2023, 24 patients with a median age of 59 years (ranged from 38 to 75 years) were enrolled. All patients were capable for efficacy analysis, of which 21 patients achieved partial response, 1 had stable disease and 2 progressive disease. The 6-month PFS rate in evaluable patients was 58.82% (10/17). The ORR and DCR were 87.50% and 91.67%, respectively. During the course of therapy, most common grade 3 or worse treatment-related adverse events were increased AST level (4.17%), increased ALT level (4.17%), increased γ-GT (4.17%), hypertension (4.17%) and hypetriglyceridemia (4.17%). Common grade 1-2 adverse reactions included nausea (66.67%), vomiting(66.67%), anemia(50.00%), increased γ-GT (20.83%) and proteinuria (20.83%). The treatment was well tolerated and no toxic death occurred. All the adverse events can be controlled and alleviated after symptomatic treatment.
Conclusions
The significant benefit and controllable security reflected by the camrelizumab in combination with chemotherapy and apatinib could support this combination as a new first-line treatment option for this population.
Clinical trial identification
ChiCTR2000035599.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract